Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 2/20 | 0.47 |
| ▸ | CPA3 | P15088 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825959 | 1.00 | ATM (0.55) | ATMSYKCTSSCTSKCTSL | |
| SCHEMBL1186455 | 1.00 | ATM (0.55) | ATMSYKCTSSCTSKCTSL | |
| SCHEMBL13816316 | 0.89 | SYK (0.56) | ATMSYKCTSSCTSKCTSL | |
| SCHEMBL990242 | 0.88 | CTSS (0.53) | ATMSYKCTSSCTSKCTSL | |
| SCHEMBL2799300 | 0.88 | GAA (0.50) | ATMSYKCTSSCTSKCTSL | |
| SCHEMBL3697318 | 0.88 | CTSS (0.56) | ATMSYKCTSSCTSKMEN1 | |
| SCHEMBL2799041 | 0.88 | GAA (0.50) | ATMSYKCTSSCTSKCTSL | |
| SCHEMBL16798329 | 0.88 | CTSS (0.56) | ATMSYKCTSSCTSKCTSL | |
| SCHEMBL12101475 | 0.88 | MEN1 (0.47) | ATMSYKCTSSCTSKCTSL | |
| SCHEMBL30718545 | 0.88 | CYP17A1 (0.47) | ATMSYKCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| EP-4532484-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-119173509-A | ROCK inhibitors and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-3825322-B1 | POLYPEPTIDE COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND APPLICATION THEREOF | CHENGDU SINTANOVO BIOTECHNOLOGY CO LTD (CN) | 2024-03-20 | — | — | EP | disclosed |
| EP-3521301-B1 | POLYAMIDE COMPOUND AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023226965-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| US-11643436-B2 | Polypeptide compound, pharmaceutical composition, preparation method and application thereof | CHENGDU SINTANOVO BIOTECHNOLOGY CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| US-11084847-B2 | Polyamide compound and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| EP-3825322-A1 | POLYPEPTIDE COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND APPLICATION THEREOF | Chengdu Sintanovo Biotechnology Co., Ltd (CN) | 2021-05-26 | — | — | EP | disclosed |
| WO-2016109515-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
| CN-104470899-A | 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors | FIBROGEN INC | 2015-03-25 | — | — | CN | disclosed |
| EP-2834220-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | Fibrogen, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| US-20150038528-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. | 2015-02-05 | — | — | US | disclosed |
| WO-2013134660-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| US-7820858-B2 | Concise β2-amino acid synthesis via organocatalytic aminomethylation | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1625153-B1 | ACYLATED LYSOBACTIN-TYPE NONADEPSIPEPTIDES | AICURIS GMBH & CO KG (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-20080058548-A1 | CONCISE BETA2-AMINO ACID SYNTHESIS VIA ORGANOCATALYTIC AMINOMETHYLATION | WISCONSIN ALUMNI RESEARCH FOUNDATION (WARF) (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084847-B2 | Polyamide compound and use thereof | OPRK1, OPRM1, OPRD1 | ATM 4737/4885SYK 2621/4885CTSS 1537/4885 |
| US-11643436-B2 | Polypeptide compound, pharmaceutical composition, preparation method and application thereof | OPRL1, OPRK1, OPRM1 | ATM 4820/4885SYK 2458/4885CTSS 2397/4885 |
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | ATM 1532/4885SYK 1211/4885CTSS 2671/4885 |
| US-20080058548-A1 | CONCISE BETA2-AMINO ACID SYNTHESIS VIA ORGANOCATALYTIC AMINOMETHYLATION | BCAT2, AADAT, BCAT1 | ATM 2146/4885SYK 3374/4885CTSS 3797/4885 |
| US-20150038528-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | EGLN3, HIF1AN, EGLN2 | ATM 4165/4885SYK 4227/4885CTSS 4622/4885 |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | ATM 2424/4885SYK 2656/4885CTSS 595/4885 |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | ATM 2424/4885SYK 2656/4885CTSS 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.